Goldline Pharmaceutical Limited was originally incorporated in Maharashtra as a private limited company in August 2004. In July 2013, it converted into a public limited company and adopted its current name. The company operates from its registered office in Nagpur and is led by its Promoters, Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal, who possess several decades of experience in the pharmaceutical industry. The company is primarily engaged in the marketing and distribution of pharmaceutical products under its own brand name, “Goldline”. It operates using an asset-light business model, where it does not manufacture its own products but instead engages third-party contract manufacturers. These manufacturers produce formulations based on the company's market research, demand analysis, and specific quality requirements. The company’s product portfolio is highly diversified and organized into five distinct segments: Goldline Pharma (general specialties), Goldline Cardinal (cardio-diabetic chronic care), Goldline Aayushman (paediatric and gynaecology), Goldline InLife (critical care), and Goldline Wellness (holistic health). This range allows the company to cater to various medical specialties including orthopedics, urology, gastroenterology, and neurology. Operationally, the company depends on a network of 8 distributors and 15 manufacturers to maintain its supply chain. While it currently operates across several Indian states including Maharashtra, Madhya Pradesh, and Odisha, it is significantly concentrated in Maharashtra, which accounted for over 44% of its revenue in the most recent nine-month period. The company plans to use the IPO proceeds to strengthen its financial position by repaying outstanding borrowings and funding general corporate growth initiatives As per financial performance, Goldline Pharmaceutical Limited has posted total income / net profits of Rs 19.84 / 0.25 Cr (FY23), 23.56 / Rs 1.80 Cr (FY24), Rs 28.05 Cr / 2.83 Cr (FY25) and Rs 21.40 Cr / 2.22 Cr (UptoQ3 FY26). So as per previous financials data, company has shown good growth, but trade receivables to total sales ratio is around 38% and 60% for FY25 and 9M FY26. Company has an average EPS of Rs 3.13 and average RoNW of 22.06% for last three fiscals. Issue is priced at a P/BV of 2.81 as per NAV of Rs 15.29/- as on 31.12.25 If we attribute latest earnings of FY24, FY25 and annualised FY26 on equity post issue, then asking price is at a P/E of around 22.88, 14.58 and 13.93 respectively. As per RHP, comparison between listed peers is shown in above table. On BRLM's front, Cumulative Capital Private Limited is associated with this IPOs, and has handled 6 IPOs in last three fiscal years. From last six IPOs, all opened above issue price or at par, on the day of listing. As of now, from last 6 IPOs, all are trading above issue price or at par. (as on 08.05.26 ) As per financials, Goldline Pharmaceutical Limited has shown good growth, RoNW is 27.37% and P/E is 22.88, 14.58 and 13.93 respectively as per FY24, FY25 and annualised FY26 earnings. So issue looks fully priced. But, higher trade receivables raises doubts. The company is primarily engaged in the marketing and distribution of pharmaceutical products under its own brand name, 'Goldline', which is highly competitive business segment. Performance of BRLM is good. So, we give NEUTRAL rating for this IPO. Readers must consult a qualified financial advisor prior to making any actual investment decisions.
✍️ Post a Comment